241 related articles for article (PubMed ID: 15821041)
1. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Tahara H; Kusuhara H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
[TBL] [Abstract][Full Text] [Related]
2. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
[TBL] [Abstract][Full Text] [Related]
3. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Ohashi R; Kamikozawa Y; Sugiura M; Fukuda H; Yabuuchi H; Tamai I
Drug Metab Dispos; 2006 May; 34(5):793-9. PubMed ID: 16455807
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice.
Tian X; Zamek-Gliszczynski MJ; Li J; Bridges AS; Nezasa K; Patel NJ; Raub TJ; Brouwer KL
Drug Metab Dispos; 2008 Jan; 36(1):61-4. PubMed ID: 17913796
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
6. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
Liu S; Beringer PM; Hidayat L; Rao AP; Louie S; Burckart GJ; Shapiro B
J Clin Pharmacol; 2008 Aug; 48(8):957-65. PubMed ID: 18511651
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
Kalvass JC; Olson ER; Pollack GM
Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of fexofenadine enantiomers.
Miura M; Uno T
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):69-74. PubMed ID: 19947891
[TBL] [Abstract][Full Text] [Related]
10. Fexofenadine in horses: pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment.
Olsén L; Ingvast-Larsson C; Larsson P; Broström H; Bondesson U; Sundqvist M; Tjälve H
J Vet Pharmacol Ther; 2006 Apr; 29(2):129-35. PubMed ID: 16515667
[TBL] [Abstract][Full Text] [Related]
11. Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats.
Ujie K; Oda M; Kobayashi M; Saitoh H
Int J Pharm; 2008 Sep; 361(1-2):7-11. PubMed ID: 18572335
[TBL] [Abstract][Full Text] [Related]
12. Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.
Kitamura Y; Koto H; Matsuura S; Kawabata T; Tsuchiya H; Kusuhara H; Tsujimoto H; Sugiyama Y
Drug Metab Dispos; 2008 May; 36(5):807-10. PubMed ID: 18299336
[TBL] [Abstract][Full Text] [Related]
13. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
Yamada S; Yasui-Furukori N; Akamine Y; Kaneko S; Uno T
Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315
[TBL] [Abstract][Full Text] [Related]
14. The effect of rifampin administration on the disposition of fexofenadine.
Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
[TBL] [Abstract][Full Text] [Related]
15. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
Poirier A; Funk C; Scherrmann JM; Lavé T
Mol Pharm; 2009; 6(6):1716-33. PubMed ID: 19739673
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
Grauer MT; Uhr M
J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
[TBL] [Abstract][Full Text] [Related]
18. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
Tian X; Li J; Zamek-Gliszczynski MJ; Bridges AS; Zhang P; Patel NJ; Raub TJ; Pollack GM; Brouwer KL
Antimicrob Agents Chemother; 2007 Sep; 51(9):3230-4. PubMed ID: 17576841
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
[TBL] [Abstract][Full Text] [Related]
20. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
